Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients

Roberto Testa, A. R. Bonfigli, C. Sirolla, M. Boemi, S. Manfrini, D. Mari, I. Testa, E. Sacchi, C. Franceschi

Research output: Contribution to journalArticle

Abstract

Plasminogen activator inhibitor type 1 (PAI-1) is an independent cardiovascular risk factor and increases in patients with Type 2 diabetes mellitus. The 4G/5G polymorphism of PAI-1 has been reported to be involved in the incidence of cardiovascular disease by regulation of PAI-1 levels, but this relation is still under debate. The aim of the study was to test the effect of 4G/5G polymorphism on the lowering of PAI-1 levels in Type 2 diabetic patients during vitamin E supplementation. Ninety-three Type 2 diabetic subjects (age±SD, 62.1±6.1 yr) were enrolled and treated with vitamin E (500 IU/die for 10 weeks. We determined the 4G/5G polymorphism and PAI-1 activity at baseline, during (5th and 10th week) and after (30th week) vitamin E supplementation. No significant differences were found in PAI-1 and its determinants among the three genotypic groups at baseline. Decrements were detected in the whole group in PAI-1 at the 5th and the 10th week from baseline followed by an increase at the 30th week (p

Original languageEnglish
Pages (from-to)217-221
Number of pages5
JournalDiabetes, Nutrition and Metabolism - Clinical and Experimental
Volume17
Issue number4
Publication statusPublished - Aug 2004

Keywords

  • PAI-1 genotype
  • Plasminogen activator inhibitor type 1
  • Type 2 diabetes mellitus
  • Vitamin E

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Internal Medicine
  • Endocrinology
  • Food Science
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients'. Together they form a unique fingerprint.

  • Cite this